Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Sells $3,424,031.80 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CAO Michael Megna sold 36,260 shares of the business’s stock in a transaction on Friday, October 30th. The stock was sold at an average price of $94.43, for a total transaction of $3,424,031.80. Following the completion of the sale, the chief accounting officer directly owned 12,697 shares in the company, valued at approximately $1,198,977.71. This represents a 74.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ KNSA traded up $2.49 on Tuesday, reaching $93.29. The company had a trading volume of 1,021,631 shares, compared to its average volume of 705,858. The firm has a market cap of $7.28 billion, a price-to-earnings ratio of 71.76 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $37.02 and a fifty-two week high of $98.48. The business has a 50 day moving average of $79.39 and a two-hundred day moving average of $60.29.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.37 by $0.19. The firm had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. As a group, research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.26 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on KNSA. JPMorgan Chase & Co. raised their price objective on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an “overweight” rating in a research report on Friday. The Goldman Sachs Group upped their target price on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Canaccord Genuity Group raised their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, Citigroup raised their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $100.57.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several large investors have recently added to or reduced their stakes in the business. Allworth Financial LP increased its holdings in Kiniksa Pharmaceuticals International by 42.0% in the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock worth $29,000 after purchasing an additional 134 shares in the last quarter. Curry Webb Wealth Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter worth approximately $29,000. KBC Group NV bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $34,000. Nykredit A S bought a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $34,000. Finally, USA Financial Formulas acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter worth approximately $69,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.